about
Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substratesPhase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.Diflomotecan. Ipsen.Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumoursDiflomotecan, a promising homocamptothecin for cancer therapy
P921
Q28200522-F3736EB0-6367-4AC2-80F7-C57C2695C8A9Q33193532-1AED24A1-B562-4A26-A9E8-0C79EB3F727FQ35026064-C2276141-CD6C-4247-97B4-B73F63BB7B7CQ35686651-A31B1568-D820-4982-B640-B22AF98A99B0Q40967654-EA1D0DB9-85C4-4966-B64A-1A3808FED1FEQ44960521-8C55ADE3-8418-4B62-A8BC-AE1B03EAD263Q46463178-F75EE935-3633-487C-95D7-3E570DB522ADQ46784441-18C1FC05-5B54-450F-8524-ACC218B08B53Q79831019-3233C39C-1B32-4906-BF53-6818CF50C2E9Q82824801-5737DFC5-BBC0-4858-AA8A-2303992324A6
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
diflomotecan
@en
type
label
diflomotecan
@en
prefLabel
diflomotecan
@en
P592
P661
P662
P683
P2017
CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O
P2067
P231
220997-97-7
P233
CCC1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O
P234
1S/C21H16F2N2O4/c1-2-21(28)7-1 ...... 3-6,28H,2,7-9H2,1H3/t21-/m1/s1
P235
LFQCJSBXBZRMTN-OAQYLSRUSA-N
P274
C₂₁H₁₆F₂N₂O₄
P592
CHEMBL306280
P652
QKT1LC4J1P